Plus Therapeutics, Inc.

The CNSide platform launch and leptomeningeal metastases (LM) opportunity are seen as transformative catalysts. Maxim maintains a Buy rating, highlighting meaningful clinical and commercial upside, while one analyst raised the 12-month price target to $20.50 citing significant market opportunities and clinical progress.

Despite positive long-term prospects, analysts have sharply revised execution risk upward. Maxim slashed its price target from $37.50 to $12, and D. Boral Capital downgraded the stock to Hold, warning that commercialization timelines may be slower than expected and that capital risk has become more prominent.

Plus Therapeutics demonstrated near-term financial resilience by raising $18 million in Q1 and maintaining a solid balance sheet with $10 million in cash and no debt, providing a runway into 2026 and supporting the company's ability to advance its pipeline without immediate funding pressure.

The 1-for-25 reverse stock split enacted to preserve Nasdaq listing compliance has raised serious concerns about capital market health. D. Boral Capital downgraded the stock, noting that reverse splits in small-cap biotech typically signal capital market strain, pressure trading liquidity, and can take meaningful time to repair the shareholder base.

With an average analyst price target of approximately $7.91–$8.00 against a stock price near $0.59–$3.74, analysts forecast upside exceeding 900%. Revenue is projected to grow at 53.3% per annum and EPS at 59.2% per annum, with the company expected to reach profitability faster than the savings rate benchmark.

Analysts have repeatedly and significantly cut price targets — including a reduction of $25.50 in one revision cycle — reflecting growing concern over dilution, elevated discount rates, and slower-than-expected revenue conversion. ChartMill assigns PSTV a fundamental rating of just 2/10, with 87.6% of all stocks outperforming it.